Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma

Naoto Fujita, Ryoji Kobayashi, Yoshiko Atsuta, Fuminori Iwasaki, Junji Suzumiya, Yoji Sasahara, Masami Inoue, Katsuyoshi Koh, Tsukasa Hori, Hiroaki Goto, Tatsuo Ichinohe, Yoshiko Hashii, Koji Kato, Ritsuro Suzuki, Tetsuo Mitsui

Research output: Contribution to journalArticle

Abstract

We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. 55%; P = 0.036). Multivariate analysis of survival rates identified allogeneic graft, Burkitt histology, and lack of response to chemotherapy as poor prognostic factors for survival. The cumulative incidence of treatment-related mortality (TRM) was significantly higher in allo-HSCT compared to auto-HSCT recipients (P = 0.017), explaining the difference in survival rates. In patients with Burkitt lymphoma (BL), overall survival was significantly inferior in the group of patients undergoing HSCT within 12 months from the initial diagnosis (P = 0.039). These data indicate that treatment outcomes for HSCT in children and adolescents with B-NHL were better in autograft recipients, suggesting that greater attention should be paid to the risk of TRM, especially after allografts, for patients with BL.

Original languageEnglish
Pages (from-to)483-490
Number of pages8
JournalInternational journal of hematology
Volume109
Issue number4
DOIs
Publication statusPublished - Apr 5 2019

Fingerprint

Hematopoietic Stem Cell Transplantation
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Burkitt Lymphoma
Survival Rate
Transplants
Survival
Mortality
Autografts
Survival Analysis
Allografts
Registries
Histology
Japan
Multivariate Analysis
Retrospective Studies
Drug Therapy
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. / Fujita, Naoto; Kobayashi, Ryoji; Atsuta, Yoshiko; Iwasaki, Fuminori; Suzumiya, Junji; Sasahara, Yoji; Inoue, Masami; Koh, Katsuyoshi; Hori, Tsukasa; Goto, Hiroaki; Ichinohe, Tatsuo; Hashii, Yoshiko; Kato, Koji; Suzuki, Ritsuro; Mitsui, Tetsuo.

In: International journal of hematology, Vol. 109, No. 4, 05.04.2019, p. 483-490.

Research output: Contribution to journalArticle

Fujita, N, Kobayashi, R, Atsuta, Y, Iwasaki, F, Suzumiya, J, Sasahara, Y, Inoue, M, Koh, K, Hori, T, Goto, H, Ichinohe, T, Hashii, Y, Kato, K, Suzuki, R & Mitsui, T 2019, 'Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma', International journal of hematology, vol. 109, no. 4, pp. 483-490. https://doi.org/10.1007/s12185-019-02608-y
Fujita, Naoto ; Kobayashi, Ryoji ; Atsuta, Yoshiko ; Iwasaki, Fuminori ; Suzumiya, Junji ; Sasahara, Yoji ; Inoue, Masami ; Koh, Katsuyoshi ; Hori, Tsukasa ; Goto, Hiroaki ; Ichinohe, Tatsuo ; Hashii, Yoshiko ; Kato, Koji ; Suzuki, Ritsuro ; Mitsui, Tetsuo. / Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma. In: International journal of hematology. 2019 ; Vol. 109, No. 4. pp. 483-490.
@article{44cc0765d22848de923553c7a7d34e61,
title = "Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma",
abstract = "We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32{\%} vs. 55{\%}; P = 0.036). Multivariate analysis of survival rates identified allogeneic graft, Burkitt histology, and lack of response to chemotherapy as poor prognostic factors for survival. The cumulative incidence of treatment-related mortality (TRM) was significantly higher in allo-HSCT compared to auto-HSCT recipients (P = 0.017), explaining the difference in survival rates. In patients with Burkitt lymphoma (BL), overall survival was significantly inferior in the group of patients undergoing HSCT within 12 months from the initial diagnosis (P = 0.039). These data indicate that treatment outcomes for HSCT in children and adolescents with B-NHL were better in autograft recipients, suggesting that greater attention should be paid to the risk of TRM, especially after allografts, for patients with BL.",
author = "Naoto Fujita and Ryoji Kobayashi and Yoshiko Atsuta and Fuminori Iwasaki and Junji Suzumiya and Yoji Sasahara and Masami Inoue and Katsuyoshi Koh and Tsukasa Hori and Hiroaki Goto and Tatsuo Ichinohe and Yoshiko Hashii and Koji Kato and Ritsuro Suzuki and Tetsuo Mitsui",
year = "2019",
month = "4",
day = "5",
doi = "10.1007/s12185-019-02608-y",
language = "English",
volume = "109",
pages = "483--490",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory B-cell non-Hodgkin lymphoma

AU - Fujita, Naoto

AU - Kobayashi, Ryoji

AU - Atsuta, Yoshiko

AU - Iwasaki, Fuminori

AU - Suzumiya, Junji

AU - Sasahara, Yoji

AU - Inoue, Masami

AU - Koh, Katsuyoshi

AU - Hori, Tsukasa

AU - Goto, Hiroaki

AU - Ichinohe, Tatsuo

AU - Hashii, Yoshiko

AU - Kato, Koji

AU - Suzuki, Ritsuro

AU - Mitsui, Tetsuo

PY - 2019/4/5

Y1 - 2019/4/5

N2 - We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. 55%; P = 0.036). Multivariate analysis of survival rates identified allogeneic graft, Burkitt histology, and lack of response to chemotherapy as poor prognostic factors for survival. The cumulative incidence of treatment-related mortality (TRM) was significantly higher in allo-HSCT compared to auto-HSCT recipients (P = 0.017), explaining the difference in survival rates. In patients with Burkitt lymphoma (BL), overall survival was significantly inferior in the group of patients undergoing HSCT within 12 months from the initial diagnosis (P = 0.039). These data indicate that treatment outcomes for HSCT in children and adolescents with B-NHL were better in autograft recipients, suggesting that greater attention should be paid to the risk of TRM, especially after allografts, for patients with BL.

AB - We undertook a retrospective study using the national registry data of hematopoietic stem cell transplantation (HSCT) in Japan to investigate the effect of graft source, particularly autologous or allogeneic tissue, on the treatment outcome in patients aged less than 18 years with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Survival analysis was conducted on 31 autologous HSCT (auto-HSCT) and 48 allogeneic HSCT (allo-HSCT) recipients between 1990 and 2013. The 5-year survival rates were significantly lower for allo-HSCT compared to auto-HSCT recipients (32% vs. 55%; P = 0.036). Multivariate analysis of survival rates identified allogeneic graft, Burkitt histology, and lack of response to chemotherapy as poor prognostic factors for survival. The cumulative incidence of treatment-related mortality (TRM) was significantly higher in allo-HSCT compared to auto-HSCT recipients (P = 0.017), explaining the difference in survival rates. In patients with Burkitt lymphoma (BL), overall survival was significantly inferior in the group of patients undergoing HSCT within 12 months from the initial diagnosis (P = 0.039). These data indicate that treatment outcomes for HSCT in children and adolescents with B-NHL were better in autograft recipients, suggesting that greater attention should be paid to the risk of TRM, especially after allografts, for patients with BL.

UR - http://www.scopus.com/inward/record.url?scp=85063783983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063783983&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02608-y

DO - 10.1007/s12185-019-02608-y

M3 - Article

C2 - 30701466

AN - SCOPUS:85063783983

VL - 109

SP - 483

EP - 490

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -